Grik4 Protein Glutamate Receptor Kainate Type Subunit 8 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
...
GRIK4 Protein - Glutamate Receptor Kainate Type Subunit 8
Grik4 Protein Glutamate Receptor Kainate Type Subunit 8 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
GRIK4 Protein (GluR8/Kainate receptor subunit 8) is encoded by the GRIK4 gene. It is a high-affinity kainate receptor subunit belonging to the ionotropic glutamate receptor family. GRIK4 forms functional kainate receptors when assembled with other subunits (GRIK1, GRIK2, GRIK3, or GRIK5), contributing to excitatory the central synaptic transmission throughout nervous system.
Protein Information
Protein Structure
GRIK4 contains several distinct structural domains that mediate its function:
Extracellular N-terminus: Contains the ligand-binding domain (LBD) formed by two polypeptide segments (S1 and S2), responsible for glutamate binding
Transmembrane domain: Three membrane-spanning helices (M1, M3, M4) that form the ion channel pore
C-terminal intracellular tail: Involved in protein-protein interactions, trafficking, and regulation
The ligand-binding domain exhibits high affinity for glutamate and related agonists, distinguishing GRIK4 from other kainate receptor subunits. This high-affinity binding is mediated by specific amino acid residues in the LBD that create a favorable binding pocket for kainate and glutamate[@porter2005].
Normal Function
Synaptic Transmission
GRIK4-containing kainate receptors play important roles in excitatory neurotransmission:
Synaptic plasticity: Contribute to both short-term and long-term plasticity at various synapses
Circuit formation: Important for neuronal circuit development and refinement during development
Calcium signaling: Permits calcium influx through the receptor channel, triggering downstream signaling cascades
Brain Region Distribution
GRIK4 shows distinct expression patterns:
[Hippocampus](/brain-regions/hippocampus): High expression in CA3 region and dentate gyrus
Cerebral [cortex](/brain-regions/cortex): Layer-specific expression in cortical [neurons](/entities/neurons)
Amygdala: Modulates emotional processing and learning
Cerebellum: Present in granule cells and molecular layer interneurons
Receptor Assembly
GRIK4 can assemble with multiple partner subunits:
GRIK4/GRIK5: High-affinity homomeric and heteromeric receptors
GRIK4/GRIK2: Heteromeric receptors with intermediate properties
GRIK4/GRIK1: Lower-affinity receptor combinations
The diversity of assembly options allows fine-tuning of receptor properties to match circuit requirements[@fisahn2004].
Disease Associations
Alzheimer's Disease
GRIK4 is implicated in Alzheimer's disease through multiple mechanisms:
Glutamate excitotoxicity: Dysregulation of kainate receptors may contribute to excitotoxic cell death
Amyloid interaction: [Aβ](/proteins/amyloid-beta) oligomers can modulate kainate receptor function
Synaptic dysfunction: Altered GRIK4 expression correlates with synaptic loss in AD models
Genetic association: GWAS studies have identified GRIK4 variants as potential AD risk factors[@contractor2003]
Depression and Psychiatric Disorders
Serotonergic interaction: GRIK4 interacts with serotoninergic systems implicated in mood regulation
Antidepressant response: Genetic variants in GRIK4 may predict response to certain antidepressants
Bipolar disorder: Association studies suggest potential links to mood disorders[@chenge2021]
Epilepsy
Seizure susceptibility: GRIK4 mutations can alter neuronal excitability
Absence seizures: Specific GRIK4 variants have been linked to absence epilepsy
Therapeutic target: Kainate receptor antagonists are being explored for seizure control[@rogawski2020]
Other Neurological Conditions
Schizophrenia: Altered GRIK4 expression in postmortem brain tissue
Autism spectrum disorders: Potential involvement in excitatory/inhibitory balance
Migraine: Possible role in cortical spreading depression
Therapeutic Targeting
Agonists
Glutamate: Endogenous agonist
Kainic acid: Potent synthetic agonist used experimentally
ATPA: Selective agonist for GluR5-containing receptors (GRIK4)
Antagonists
CNQX: Competitive antagonist
NBQX: AMPA/kainate receptor antagonist
LY466365: Selective GluR5 antagonist
Clinical Potential
Kainate receptor modulation remains an active area of drug development:
The study of Grik4 Protein Glutamate Receptor Kainate Type Subunit 8 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Lerma J, et al, (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11274345/)
[Contractor A, et al, (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/14579411/)
[Moloney PB, et al, (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35608742/)
[Jane DE, et al, (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19162057/)
[Unknown, Huettner JE (2003). 'Kainate receptors and synaptic transmission.' Progress in Neurobiology (2003)](https://pubmed.ncbi.nlm.nih.gov/14500151/)
[Porter RH, et al, (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/15733854/)
[Fisahn A, et al, (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/15519742/)
[Contractor A, et al, (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/14592445/)
[Chenge B, et al, (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34582451/)
[Rogawski MA, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32107834/)